Skip to main content

Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), CVRx (CVRX)

Tipranks - Tipranks - Sat Feb 14, 9:38AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and CVRx (CVRX – Research Report) with bullish sentiments.

Valentine's Day Sale - 70% Off

BioLife Solutions (BLFS)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions today. The company’s shares closed last Friday at $22.03.

According to TipRanks.com, Hewitt is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.8% and a 36.3% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Park Dental Partners, Inc., and Dyadic International. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $33.25 average price target, representing a 52.7% upside. In a report issued on February 5, Northland Securities also maintained a Buy rating on the stock with a $34.00 price target.

See the top stocks recommended by analysts >>

CVRx (CVRX)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on CVRx today. The company’s shares closed last Friday at $4.94.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 34.1% and a 59.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Fennec Pharmaceuticals, and Avadel Pharmaceuticals. ;'>

CVRx has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, representing an 87.5% upside. In a report released today, William Blair also maintained a Buy rating on the stock.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).